AIPPI 2017: Eli Lilly counsel discusses ‘convoluted’ Amgen v Sanofi ruling
17-10-2017
Sanofi and Regeneron secure stay of Praluent injunction
10-02-2017
ericsphotography / iStockphoto.com
The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Sanofi, Regeneron Pharmaceuticals, patent, patent infringement, evolocumab, Repatha, Praluent, injunction, US Court of Appeals for the Federal Circu
